West Pharmaceutical Services (NYSE: WST) , Five Prime Therapeutics (NASDAQ: FPRX) , and Fulgent Genetics (NASDAQ: FLGT) all have had a good run this year but are poised to climb higher. While two of them have benefited from significant pandemic tailwinds, none are "COVID stocks" in the sense they have a lot more going for them.
You may not have heard of any of these companies. Fulgent Genetics and Five Prime are small-cap stocks while West Pharmaceutical is a large-cap that just made the jump this year from mid-cap. That may explain why despite their growth, they are not overvalued, in my opinion.
Image source: Getty Images.
For further details see:
Have $1,000? Here Are 3 Top Healthcare Stocks to Buy in December